Sign in
CompletedNo phase

Self-Administered 2-Hour Oral Glucose Tolerance Test

Key facts

Who runs it
Prisma Health-Upstate
Where
Greenville, United StatesSee the site
Trial code
Status
Completed
People taking part
200 people enrolled
Started
2 Nov 2023
Ended
1 May 2025
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Self-administered oral glucose tolerance test
Record updated
2 July 2025

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part
Show the full registry criteria (12)Hide the full registry criteria

Who can take part

  • Maternal age 18 years or older
  • English or Spanish speaking
  • Diagnosis of gestational diabetes with recommendation for postpartum screening, by any of the following criteria (1) HgbA1c 5.9-6.4% at ≤ 14 6/7 weeks, (2) HgbA1c ≥ 5.9% at 15-23 6/7 weeks, (3) 50-gram oral glucose tolerance test plasma glucose value ≥ 200 mg/dL, (4) 2 or more abnormal plasma glucose values on a 100-gram oral glucose tolerance test with the following thresholds: fasting ≥ 95 mg/dL, 1 hour ≥ 180 mg/dL, 2 hour ≥155 mg/dL, 3 hour ≥140 mg/dL or (5) fasting blood glucose ≥ 126
  • No personal history of Type 1 or Type 2 diabetes defined by self-reported or documented history, or HgbA1c >/=6.5% at ≤ 14 6/7 weeks gestation
  • Antepartum care with Prisma Health affiliated obstetric practices
  • Delivery at Greenville Memorial Hospital
  • Active Epic MyChart access at time of enrollment
  • Capable of providing informed consent

Who cannot take part

  • Pre-pregnancy diagnosis of diabetes (Type 1, 2, or other form of diabetes)
  • No glucometer or supplies for fingerstick glucose monitoring, or inability to perform fingerstick glucose monitoring
  • Unable to provide informed consent
  • Inability to follow up for routine postpartum care

Where in United States

  • Prisma Health Greenville Memorial HospitalGreenville, United States

About the trial

What the trial wants to find out

The goal of this randomized controlled trial is to evaluate whether self-administered postpartum diabetes screening tests in patients with gestational diabetes improves screening completion rates. The primary question it aims to answer is:

Read full original descriptionShow less

1. Does a self-administered 75-gram oral glucose tolerance test with virtual follow-up visit increase the rate of postpartum diabetes screening within 12 weeks of delivery?

The 2 groups in the trial

  • Self-administered diabetes screenTreatment being tested

    Self-administered 75-gram oral glucose tolerance test with 4-week virtual follow-up visit. Drug: GlucoCrush

    Treatment: Self-administered oral glucose tolerance test

  • Routine postpartum careNo study treatment, for comparison

    Office based oral glucose tolerance test at 6 weeks postpartum, per normal protocol. Drug: GlucoCrush

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Self-Administered 2-Hour Oral Glucose Tolerance Test: A Randomized Controlled Trial
Record updated
2 July 2025